Hansel Comas Rojas

Dr. Hansel Comas Rojas

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
CKCaroline P Kerr
Caroline P Kerr
JSJulia Sheehan-Klenk
Julia Sheehan-Klenk
JGJoseph J. Grudzinski
Joseph J. Grudzinski
DADavid P. Adam
David P. Adam
TNThanh Phuong T. Nguyen
Thanh Phuong T. Nguyen
ZMZachary S. Morris
Zachary S. Morris
Radiopharmaceutical therapies (RPT) activate a type I interferon (IFN1) response in tumor cells. We hypothesized that the timing and amplitude of this response varies by isotope. We compared equal doses delivered by 90Y, 177Lu, and 225Ac in vitro as unbound radionuclides and in vivo when chelated to NM600, a tumor-selective alkylphosphocholine. Response in murine MOC2 head and neck carcinoma and B78 melanoma was evaluated by qPCR and flow cytometry. Therapeutic response to 225Ac-NM600+anti-CTLA4+anti-PD-L1 immune checkpoint inhibition (ICI) was evaluated in wild-type and stimulator of interferon genes knockout (STING KO) B78. The timing and magnitude of the IFN1 response correlated with radionuclide half-life and linear energy transfer. The ratio of CD8+ T cells to regulatory T cells (Treg) increased in tumors 7 days after 90Y- and 177Lu-NM600 and day 21 after 225Ac-NM600. 225Ac-NM600+ICI improved survival in mice with wild-type but not with STING KO tumors, relative to monotherapies. Thus, we have found that the immunomodulatory effects of RPT vary with radioisotope and promote tumor cell STING-dependent enhanced response to ICIs in murine models. These findings have implications for the optimization of RPT–immunotherapy combinations and could guide the relative timing of therapies, the selection of isotope, and patient selection through tumor biomarkers.

26 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKCaroline P Kerr
Caroline P Kerr
WJWonJong Jin
WonJong Jin
PLPeng Liu
Peng Liu
JGJoseph J. Grudzinski
Joseph J. Grudzinski
CFCarolina A. Ferreira
Carolina A. Ferreira
ZMZachary S. Morris
Zachary S. Morris
Radiopharmaceutical therapy (RPT) synergises with immune checkpoint inhibitors (ICI), but comparison of immunomodulation by different radioisotopes is lacking. Here, we evaluate mechanisms of response and timing of ICI administration relative to α- (225Ac) and β-emitting (90Y, 177Lu) radioisotope therapy, coupled with alkylphosphocholine NM600, when combined with dual (anti-PD-L1 and anti-CTLA4) ICI, using syngeneic poorly immunogenic (B78 and Myc-CaP) and immunogenic (MC38) murine models. Regardless of the isotope, RPT delivering 2 Gy mean tumor dose promotes tumor regression and improves survival in B78 or MC38 tumor-bearing mice when combined with early ICI administration. Greatest anti-tumor responses are seen in MC38 to 90Y-NM600 + ICI and in B78 and Myc-CaP to 225Ac-NM600 + ICI. Flow cytometry and single-cell RNA and T cell receptor sequencing reveal that, combined with ICI, β-emitting radioisotopes expand existing adaptive immunity, whereas α-emitting radiopharmaceuticals initiate immune priming. Thus, appropriate application of α- or β-emitting RPT in combination with ICI achieves distinct antitumor immune responses.

20 February 2026 in Advanced Science
Verified
Journal Article
Open access
CMCamilla Marzuoli
Camilla Marzuoli
APAndrea Pianetti
Andrea Pianetti
EMElena Mancinelli
Elena Mancinelli
AVAnthea Villano
Anthea Villano
MVMatteo Vailati
Matteo Vailati
MAMaria Rosa Antognazza
Maria Rosa Antognazza
Endothelial‐derived nitric oxide (·NO) is a key signaling molecule in the vascular system, exerting concentration‐dependent control over critical cellular functions such as angiogenesis, vascular tone, and endothelial barrier integrity. Tools for achieving reversible, spatiotemporally resolved modulation of intracellular ·NO, without pharmacological or genetic manipulation, are currently lacking. Here, we present a light‐activated, nanoparticle (NP)‐based strategy enabling bidirectional control of endogenous ·NO in endothelial cells. Composite NPs, based on poly(3‐hexylthiophene), P3HT, and poly(3,4‐ethylene‐dioxythiophene):poly(styrenesulfonate), PEDOT:PSS polymers, are efficiently internalized in human (HUVEC) and murine (H5V) endothelial cells. In dark, NP uptake induces a ROS‐dependent, intracellular ·NO increase (+50% and +100% in HUVEC and H5V, respectively, vs. controls), a metabolic shift toward glycolysis and upregulation of both endothelial nitric oxide synthase (eNOS, +50%) and induced nitric oxide synthase (iNOS, +40%). NP photostimulation reverses this response, decreasing ·NO below basal levels, up to −40% in HUVEC and H5V, via ROS‐mediated scavenging and iNOS downregulation (−40%), partially restoring oxidative phosphorylation metabolism. Importantly, the photoexcitation protocol is compatible with perspective in vivo use, in terms of source type (LEDs) and power density (6 mW/cm 2 ). Our approach represents an innovative strategy for bidirectional endothelial ·NO modulation, providing new opportunities in the emerging field of photo‐redox medicine.

9 December 2025 in Radiation
Verified
Journal Article
Open access
PDF file
CLCynthia Lilieholm
Cynthia Lilieholm
JZJennifer Zaborek
Jennifer Zaborek
OKOhyun Kwon
Ohyun Kwon
AAAdedamola O. Adeniyi
Adedamola O. Adeniyi
CKCaroline P Kerr
Caroline P Kerr
JWJamey Weichert
Jamey Weichert
Radiopharmaceutical therapy (RPT) offers tumor-selective radiation delivery and represents a promising platform for combination with immune checkpoint inhibitors (ICIs). While prior studies suggest that RPT can stimulate antitumor immunity, synergy with ICIs may depend on radionuclide properties, absorbed dose, and radiation distribution within the tumor microenvironment. This study evaluated how radionuclide selection and dose influence immune stimulation and therapeutic efficacy of GD2-targeted antibody-based RPT combined with ICIs. Dinutuximab, an anti-GD2 monoclonal antibody, was radiolabeled with β−-emitters (90Y, 177Lu) or an α-emitter (225Ac). C57Bl6 mice bearing GD2+ tumors received 4 or 15 Gy tumor-absorbed doses, determined by individualized dosimetry, with or without dual ICIs (anti-CTLA-4 and anti-PD-L1). In vivo imaging, ex vivo biodistribution, survival, histological, and gene expression analyses were performed to assess therapeutic and immunological outcomes. All radiolabeled constructs demonstrated preferential uptake in GD2+ tumors. Combination therapy improved survival in a radionuclide- and dose-dependent manner, with the greatest benefit in the 225Ac + ICI group at 15 Gy. Treatment activated type I interferon signaling and increased MHC-I and PD-L1 expression. Notably, 90Y reduced regulatory T cells, enhancing CD8+/Treg ratios, while 225Ac induced robust interferon-driven activation. Radionuclide selection and absorbed dose critically shape immune and therapeutic outcomes of antibody-based RPT combined with ICIs, underscoring the importance of delivery mechanism and dose optimization in combination therapy strategies.

1 August 2025
Verified
Other
Open access
CKCaroline P Kerr
Caroline P Kerr
JSJulia Sheehan-Klenk
Julia Sheehan-Klenk
JGJoseph J. Grudzinski
Joseph J. Grudzinski
DADavid P. Adam
David P. Adam
TNThanh Phuong T. Nguyen
Thanh Phuong T. Nguyen
ZMZachary S. Morris
Zachary S. Morris
Longitudinal Ifnb1, Mx1, Ddx58, Fas, Pdl1, and Mhc1 expression following (A) 12 Gy EBRT (MOC2) or (B) 4 Gy EBRT (B78) in vitro.

1 August 2025
Verified
Other
Open access
CKCaroline P Kerr
Caroline P Kerr
JSJulia Sheehan-Klenk
Julia Sheehan-Klenk
JGJoseph J. Grudzinski
Joseph J. Grudzinski
DADavid P. Adam
David P. Adam
TNThanh Phuong T. Nguyen
Thanh Phuong T. Nguyen
ZMZachary S. Morris
Zachary S. Morris
90Y-, 177Lu, 225Ac-NM600 modulate tumor immune cell composition in the tumor microenvironment.